$21 billion for HIV/AIDS.

Authorities will spend $21 billion for HIV/AIDS analysis, treatment, avoidance, and related actions. Is this enormous expenditure paying off? A study published in the July 1 issue of The Journal of Infectious Diseases indicates that it is – and way more than previously thought. The scholarly study, by Rochelle P. Walensky, MD, MPH, Kenneth Freedberg , MD, MSc and colleagues at Massachusetts General Hospital and various other centers appears at a time the globe contemplates the 25-12 months anniversary of the 1st reported cases of Helps and celebrates the 10-yr anniversary of the usage of multi-drug antiretroviral combos for the treatment of HIV infections .Secondary end factors included the target response rate , the duration of response , and security. Efficacy was assessed in the intention-to-treat population, with all patients included in the treatment group to that they were randomly designated. Protection was assessed in the as-treated population, that was defined as all patients who underwent randomization and who received at least one dosage of a study drug. Study Oversight The original protocol and all amendments were approved by the relevant institutional review board or independent ethics committee at each study center.